![[Toyota Times] Century as a Brand, Lexus as Innovation: All the Details on Toyota's New Project!](https://businessfortnight.com/wp-content/uploads/2025/10/Toyota-Times-Century-as-a-Brand-Lexus-as-Innovation-All-218x150.jpg "[Toyota Times] Century as a Brand, Lexus as Innovation: All the Details on Toyota's New Project!")
MIRAMAR, FL, Oct. 13, 2022 (GLOBE NEWSWIRE) — Stemtech Corporation (“Stemtech”) (OTCQB: STEK), an modern stemceuticals™ firm and a pioneer within the discipline of stem cell diet, right this moment introduced creation of recent Board of Directors for his or her Stemtech Malaysia Sdn. Bhd.
Stemtech Corporation President and Chief Operating Officer, John W. Meyer, mentioned “Stemtech Malaysia has made changes to the Board of Directors. In addition to current local Director, Mr. Shukor, Charles S Arnold, CEO Stemtech Corporation, David E. Price, Stemtech Corporation Counsel, also became directors.”
Charles S. Arnold, Stemtech Corporation Chairman and CEO elaborated that “as part of the new board, John W. Meyer, President & COO of Stemtech Corporation was elected to serve as Chairman of the Stemtech Malaysia Board of Directors. Together we reaffirm that Stemtech Corporation believes in the market opportunities which Malaysia represents, assuring our commitment to our Independent Business Partners. We expect to grow this market to new heights and with the new Board, will be able to ignite more growth.”
About Stemtech Corporation
Stemtech Corporation, a number one stemceutical™ firm with a direct gross sales distribution mannequin, was based on April 18, 2018, after buying the operations from its predecessor Stemtech International, Inc. which was based in 2005. From 2010 via 2015, Stemtech International, Inc., was acknowledged 4 separate instances on the Inc. 5000 Fastest-Growing Companies checklist. In 2018, the Company underwent an in depth government reorganization, and continued operations underneath new management. Stemtech makes a speciality of creating merchandise and formulation which are patent protected within the U.S. and in choose worldwide markets. The Company’s patented formulation assist the discharge, circulation and migration of the physique’s grownup stem cells from its bone marrow. The Company markets its merchandise underneath the next manufacturers: RCM System, stemrelease3™, Stemflo® MigraStem, OraStem® (Oral Health Care), and D-Fuze™ (EMF blocker). Its stemceutical™ merchandise are all-natural, plant-based and manufactured underneath cGMP (Current Good Manufacturing Practices) underneath the auspices of the Dietary Supplement Health and Education Act (DSHEA). For extra info, please go to www.stemtech.com.
Forward-Looking Statements
This announcement accommodates forward-looking statements inside the which means of the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Such statements embrace however usually are not restricted to statements recognized by phrases equivalent to “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “targets,” “projects” and comparable expressions. The statements on this launch are primarily based upon the present beliefs and expectations of our firm’s administration and are topic to vital dangers and uncertainties. Actual outcomes could differ from these set forth within the forward-looking statements. Numerous elements might trigger or contribute to such variations, together with, however not restricted to, outcomes of medical trials and/or different research, the challenges inherent in new product growth initiatives, the impact of any aggressive merchandise, our capability to license and defend our mental property, our capability to boost extra capital sooner or later that’s essential to take care of our business, modifications in authorities coverage and/or regulation, potential litigation by or towards us, any governmental assessment of our merchandise or practices, in addition to different dangers mentioned occasionally in our filings with the Securities and Exchange Commission, together with, with out limitation, our newest 10-Q Report filed on August 23, 2022. We undertake no responsibility to replace any forward-looking assertion, or any info contained on this press launch or in different public disclosures at any time. Finally, the investing public is reminded that the one bulletins or details about Stemtech Corporation that are condoned by the Company should emanate from the Company itself and bear our title as its Source.
www.Stemtech.com
Investor Relations:
Investor Relations: 954-715-6000 ext 1040
[email protected]
